LIDDS AB (publ) (STO:LIDDS)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.0950
+0.0050 (5.56%)
Jul 8, 2025, 9:00 AM CET
-31.65%
Market Cap 12.28M
Revenue (ttm) 9.00K
Net Income (ttm) -7.24M
Shares Out 136.46M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,000
Average Volume 138,593
Open 0.0950
Previous Close 0.0900
Day's Range 0.0950 - 0.0950
52-Week Range 0.0304 - 0.2300
Beta 0.35
RSI 68.35
Earnings Date Aug 28, 2025

About LIDDS AB

LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, whic... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol LIDDS
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.